1. Thailand Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

1.71
THB
-0.02
(-1.16%)
0.05EPS
19.50P/E
830.51MMarket Cap
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited
SET:JSP
(Stock Exchange of Thailand)

Recent

price

1.71

P/E

ratio

19.50

div

yld

5.68%

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
THB
0.79
1
1.17
1.01
1.23
1.74
2.13
2
Revenue per Share
0.05
0.07
0.08
-0.01
0.06
0.01
0.14
0.09
Basic EPS, GAAP
0.07
0.08
0.04
-0.63
-0.28
0.16
-0.31
-0.34
Free Cash Flow per Basic Share
- -
0.07
0.08
0.01
0.02
0.03
0.05
0.1
Dividend per Share
0.36
0.43
2.12
2.31
1.83
1.81
1.91
1.88
Book Value per Share
0.35
0.42
2.11
2.29
1.75
1.73
1.84
1.81
Tangible Book Value per Share
455
455
360
455
469
475
475
478
Basic Weighted Avg Shares
361
456
422
458
576
824
1,010
957
Sales/Revenue/Turnover
10.85
12.12
11.44
-0.2
-0.19
12.74
11.36
9.32
Operating Margin (%)
16
22
22
27
48
62
70
68
Depreciation Expense
24
31
30
-3
29
5
68
43
Net Income, GAAP
21.68
21.66
20.68
- -
24.94
- -
54.84
65.36
Effective Tax Rate (%)
6.53
6.82
7.03
-0.67
5.09
0.55
6.72
4.49
Profit Margin (%)
-96
-51
710
376
51
84
91
69
Working Capital
65
97
168
152
182
186
272
246
LT Debt
165
196
966
1,050
932
883
927
915
Total Equity
- -
10.85
4.94
- -
-0.07
- -
4.18
2.45
Return on Invested Capital (%)
- -
10.42
4.88
- -
3.33
- -
7.84
5.41
Return on Capital (%)
- -
17.23
5.11
-0.3
3.06
0.52
7.68
4.8
Return on Common Equity (%)

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
109
144
142
LT Borrowings
233
221
210
LT Finance Leases
39
37
36
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
475
475
475
Market Capitalization
902
925
831

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
328
351
321
Cash, Cash Equivalents & STI
48
46
43
Accounts Receivable, Net
151
145
132
Inventories
101
129
120
Total Current Liabilities
237
263
252
Payables & Accruals
112
107
97
ST Debt
109
144
142
Deferred Revenue
15
13
13

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
78.08%
5.04%
Free Cash Flow
- -
-527.03%
-298.16%
Net Income, GAAP
- -
28.93%
1,399.98%
Sales/Revenue/Turnover
- -
18.51%
22.53%
Total Cash Common Dividend
- -
18.88%
66.42%

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
156
199
229
241
824
2025
228
263
261
258
1,010
2026
201
237
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.03
0.07
-0.08
0.01
2025
0.02
0.06
0.03
0.04
0.14
2026
- -
0.02
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
- -
0.03
2025
- -
- -
0.05
- -
0.05
2026
- -
0.04
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. (JSP.BK) develops, manufactures and distributes pharmaceuticals, dietary supplements, traditional medicines, herbal products, hemodialysis solutions and related medical supplies in Thailand. The company provides contract manufacturing services (OEM) for client brands as well as produces and sells own-brand products under trademarks including COX, Suphap Osot, EVITON and JSP; its dietary supplements encompass collagen peptides, multivitamins, 4 Mix Oil, Wolffia Cap, Acerola Cherry, coconut oil, fish oil, spirulina and beta-glucans; conventional medicines feature cough syrups and contraceptives; herbal and traditional medicines include Andrographis Paniculata pills, Curcuma Longa capsules, Compound Senna Laxative capsules, herbal cough lozenges and Reishi supplements, all produced under GMP/PIC/s standards; additional offerings comprise cosmetics, sanitizers, drug test kits and laboratory research, testing, training and consultancy services via subsidiaries. Operations span facilities in Bangkok and Lamphun province, targeting domestic markets with expansion into CLMV countries including Cambodia, Laos, Myanmar and Vietnam; founded in 2005 through the Daengprasert family's expansion from earlier pharmacy and COX Laboratories ventures dating to 1954, JSP is headquartered at 255/257 Soi Sathupradit 58, Yannawa, Bangkok. Recent developments include the 2023 establishment of subsidiaries JSP Pharma Holding Company Limited and full acquisition of CDIP (Thailand) Public Co., Ltd. for research services plus 52.8% stake in Grace Water Med Co., Ltd. for hemodialysis production; 2024 initiatives encompass relocation of dietary supplement production to Lamphun, expiration of JSP-W1 warrants yielding Baht 48.9 million, issuance of JSP-W2 warrants, capital adjustments and ongoing R&D in Wolffia extracts, hemp-derived herbs and chewable soft-gelatin capsules alongside expansion of conventional medicine lines to 20-25 million bottles annually.